Universities Receive $100 Million for Biomedical Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

LOS ANGELES--California businessman Alfred E. Mann has donated $100 million each to the University of Southern California (USC) and the University of California at Los Angeles (UCLA) to set up institutes for biomedical research.

 LOS ANGELES--California businessman Alfred E. Mann has donated $100 million each to the University of Southern California (USC) and the University of California at Los Angeles (UCLA) to set up institutes for biomedical research.

At USC, the Alfred E. Mann Institute for Biomedical Engineering will be based on the University’s campus in a building that will also house the Department of Biomedical Engineering. USC president Dr. Steven Sample said that the institute would serve as a bridge between the university and the biomedical industry. Mr. Mann said he hopes the new institutes will encourage development of biotechnology companies in the Los Angeles area.

The gift to UCLA is one of the largest donations ever to a public university. The agreement for the UCLA institute is still being developed.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video